ALNY vs MED · P/E 76, rev $1.29B vs rev $152.4M
Alnylam Pharmaceuticals Inc (ALNY) versus MEDIFAST INC (MED) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
MEDIFAST INC (MED) is a personal services company listed on NYSE.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported MED revenue for 2026-06-30 was $152.4M. Net income was -$5.2M. MED currently screens at market cap $125.3M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. MED currently screens at market cap $125.3M.
Not investment advice. Open the ALNY and MED stock pages for the full models.
Not investment advice.